[High-dose therapy with autologous stem cell support in malignant lymphoma and breast cancer. Experiences with hematopoietic stem cells isolate from blood].
Since 1994, 17 breast cancer patients and 16 lymphoma patients have been treated at the Norwegian Radium Hospital with high-dose therapy supported by autologous peripheral progenitor cells. All the patients were given granulocyte colony stimulating factor in the recovery phase after cytotoxic treatment in order to mobilize and harvest peripheral progenitor cells. Aphareses were successful in all patients and the mean number of CD34 cells reinfused per kilo body weight was 7.05 x 10(6) for the lymphoma patients and 11.1 x 10(6) for the breast cancer patients. The mean time to recover > or = 0.5 x 10(9)/l granulocytes and > or = 20 x 10(9)/l platelets after reinfusion of stem cells was 10 days and 11.7 days respectively for the lymphoma patients, while the breast cancer patients engrafted at day 8.6 and day 9.3. No severe treatment-related complications were observed.
Kolstad
A
A
Onkologisk avdeling, Det Norske Radiumhospital, Oslo.
Holte
H
H
Kvaløy
S
S
Jakobsen
E
E
Erikstein
B
B
Aurlien
E
E
Kvalheim
G
G
Bøhler
P J
PJ
Langholm
R
R
D000328:Adult; D001943:Breast Neoplasms / Q000097:blood / Q000532:radiotherapy / Q000628:therapy*; D002469:Cell Separation; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008223:Lymphoma / Q000097:blood / Q000532:radiotherapy / Q000628:therapy*; D008875:Middle Aged; D011879:Radiotherapy Dosage; D014182:Transplantation, Autologous